Relapsing-Remitting Multiple Sclerosis Patients' Experience with Natalizumab
نویسندگان
چکیده
منابع مشابه
Natalizumab in relapsing-remitting multiple sclerosis.
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab was indicated in active RRMS, mostly as a sec...
متن کاملNatalizumab: A new treatment for relapsing remitting multiple sclerosis
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin. In a Phase 3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) by 68% compared with placebo (p < 0.001) and the risk of sustained disability progression was reduced by 42% in the nataliz...
متن کاملUse of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
OBJECTIVE To evaluate the outcomes of patients with multiple sclerosis (MS) who were treated with natalizumab in Kuwait. MATERIALS AND METHODS A retrospective study using the MS registry to identify patients who were treated with natalizumab was conducted. Patients' demographics, clinical characteristics and treatment parameters were collected at baseline and last follow-up visit. Primary out...
متن کاملTH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
BACKGROUND The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in relapsing-remitting MS (RRMS) patients receiving an immunosuppressive treatment with ...
متن کاملNatalizumab for relapsing multiple sclerosis.
To the Editor: As Ropper pointed out in his editorial (March 2 issue),1 the three articles on the use of natalizumab in that issue of the Journal are pivotal, but his conclusion that natalizumab is “a potent treatment for multiple sclerosis” may be too sanguine. The similar entry criteria, treatment, and methods of analysis permit clinically useful conclusions to be drawn from the placebocontro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of MS Care
سال: 2012
ISSN: 1537-2073
DOI: 10.7224/1537-2073-14.1.39